The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis.

Ann Clin Transl Neurol · 2018 · PMC5989754 · PMID 29928650

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Interestingly, also the age of the patient at the time of treatment initiation showed a trend to influence the chance to achieve NEDA (Fig. 3 D).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.